Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Cytomegalovirus (CMV or HHV-5) is a contagious infection caused by a member of the herpes virus family. CMV is spread through saliva or urine. The symptoms of CMV include fever, pneumonia, weight loss, hearing, neurological and developmental problems. Exposure to direct contact with an infected surface or organism, weakened immune system and congenital factors are some predisposing factors of HHV-5.

The CMV pipeline drugs market research report provides comprehensive information on the therapeutics under development for CMV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for CMV and features dormant and discontinued projects.

CMV Pipeline Drugs Market Segmentation by Targets

Some of the targets of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein among others. Human Cytomegalovirus Envelope Glycoprotein B leads this segment of the CMV pipeline drugs market.

CMV Pipeline Drugs Market Analysis, by Targets

CMV Pipeline Drugs Market Analysis, by Targets

For more CMV pipeline drugs market target insights, download a free report sample

CMV Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist among others. Human Cytomegalovirus Envelope Glycoprotein B Inhibitor leads the CMV pipeline drugs market in terms of MoA.

CMV Pipeline Drugs Market Analysis, by Mechanisms of Action

CMV Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the CMV pipeline drugs market, download a free report sample

CMV Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the CMV pipeline drugs market are intravenous, intramuscular, oral, parenteral, intradermal, subcutaneous, and intravenous bolus. Intravenous leads the CMV pipeline drugs market in terms of RoA.

CMV Pipeline Drugs Market Analysis, by Routes of Administration

CMV Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the CMV pipeline drugs market, download a free report sample

CMV Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the CMV pipeline drugs market are Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine among others. Cell Therapy leads the CMV pipeline drugs market in terms of molecule types.

CMV Pipeline Drugs Market Analysis, by Molecule Types

CMV Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the CMV pipeline drugs market, download a free report sample

CMV Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the CMV pipeline drugs market are Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc among others. Merck & Co Inc has the highest number of products under development.

Acer Therapeutics Inc: Acer Therapeutics Inc (Acer), is a Pharmaceutical company. It offers commercialize therapies for patients with serious rare diseases. Its pipeline product portfolio includes EDSIVO, for the treatment of vascular ehlers-danlos syndrome; ACER-001, a taste-masked, immediate-release formulation of sodium phenylbutyrate for urea cycle disorders (UCDs) and maple syrup urine disease (MSUD); osanetant, a neurokinin 3 receptor antagonist against induced vasomotor symptoms and emetine for infectious diseases. Acer uses a T-cell technology platform for the development of patient-specific T-cell therapies. The company operates manufacturing facilities, and research and development facilities in the US and Canada. Acer is headquartered in Newton, Massachusetts, the US.

CMV Pipeline Drugs Market Analysis, by Companies

CMV Pipeline Drugs Market Analysis, by Companies

To know more about the CMV pipeline drugs market companies, download a free report sample

CMV Pipeline Drugs Market Report Overview

Key Targets Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein
Key Mechanisms of Action Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist
Key Routes of Administration Intravenous, Intramuscular, Oral, Parenteral, Intradermal, Subcutaneous, and Intravenous Bolus
Key Molecule Types Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine
Key Companies Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of CMV.
  • The pipeline guide reviews pipeline therapeutics for CMV by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in CMV therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates CMV therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for CMV

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for CMV.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the CMV pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Abhelix LLC
Acer Therapeutics Inc
AlloVir Inc
AlphaVax Inc
Artemis Therapeutics Inc
Biotest AG
Chengdu Rongsheng Pharmaceutical Co Ltd
China Biologic Products Holdings Inc
China Immunotech Co Ltd
Citranvi Biosciences LLC
Cyrus Biotechnology Inc
Danuvius BioSciences
Evrys Bio
GSK plc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Huinuo Biomedical Technology Co Ltd
iCELL Biotechnology Co Ltd
Immunetune BV
Karyopharm Therapeutics Inc
Lion TCR Pte Ltd
Memo Therapeutics AG
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Nobelpharma Co Ltd
Okogen Inc
Phoenix Biotechnology Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
Savoy Pharmaceuticals Inc
Shanxi Kangbao Biological Product Co Ltd
SL VaxiGen Inc
SpyBiotech Ltd
Stadius Biopharma LLC
Synklino ApS
Takeda Pharmaceutical Co Ltd
Trellis Bioscience Inc
VBI Vaccines Inc
Vichem Chemie Research Ltd
Viramatix Sdn Bhd
ViroKyne Therapeutics LLC
Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cytomegalovirus (HHV-5) Infections – Overview

Cytomegalovirus (HHV-5) Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cytomegalovirus (HHV-5) Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cytomegalovirus (HHV-5) Infections – Companies Involved in Therapeutics Development

Cytomegalovirus (HHV-5) Infections – Drug Profiles

Cytomegalovirus (HHV-5) Infections – Dormant Projects

Cytomegalovirus (HHV-5) Infections – Discontinued Products

Cytomegalovirus (HHV-5) Infections – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022

Cytomegalovirus (HHV-5) Infections – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the CMV pipeline drugs market?

    Some of the targets of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein.

  • What are the key mechanisms of action in the CMV pipeline drugs market?

    Some of the mechanisms of action of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist.

  • What are the key routes of administration in the CMV pipeline drugs market?

    The key routes of administration in the CMV pipeline drugs market are intravenous, intramuscular, oral, parenteral, intradermal, subcutaneous, and intravenous bolus.

  • What are the key molecule types in the CMV pipeline drugs market?

    The molecule types in the CMV pipeline drugs market are Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine.

  • Which are the leading companies in the CMV pipeline drugs market?

    Some of the leading companies in the CMV pipeline drugs market are Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc.

Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.